What personal data we collect and why we collect it
Comments
When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection.
An anonymized string created from your email address (also called a hash) may be provided to the Gravatar service to see if you are using it. The Gravatar service privacy policy is available here: https://automattic.com/privacy/. After approval of your comment, your profile picture is visible to the public in the context of your comment.
Media
If you upload images to the website, you should avoid uploading images with embedded location data (EXIF GPS) included. Visitors to the website can download and extract any location data from images on the website.
Contact forms
Cookies
If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year.
If you visit our login page, we will set a temporary cookie to determine if your browser accepts cookies. This cookie contains no personal data and is discarded when you close your browser.
When you log in, we will also set up several cookies to save your login information and your screen display choices. Login cookies last for two days, and screen options cookies last for a year. If you select “Remember Me”, your login will persist for two weeks. If you log out of your account, the login cookies will be removed.
If you edit or publish an article, an additional cookie will be saved in your browser. This cookie includes no personal data and simply indicates the post ID of the article you just edited. It expires after 1 day.
Embedded content from other websites
Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website.
These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.
Analytics
Who we share your data with
How long we retain your data
If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue.
For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.
What rights you have over your data
If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.
Where we send your data
Visitor comments may be checked through an automated spam detection service.
Your contact information
Additional information
How we protect your data
What data breach procedures we have in place
What third parties we receive data from
What automated decision making and/or profiling we do with user data
美國波士頓的兩家醫學研究中心正進行一項全球性的臨床人體試驗,研究一種試驗性的藥物是否能幫助患有一種致命疾病的患者來延長生命。Dana-Farber 癌症研究所以及波士頓大學醫學院的 Boston Medical Center,是參與這項第3期確認性AFFIRM-AL臨床試驗的主要醫學中心。該試驗測試由Prothena Biosciences公司所研製的試驗性藥物birtamimab,用於AL類澱粉樣變晚期(Mayo第四期)的患者。
AL 類澱粉沉積症的成因目前尚不完全明瞭,但它與骨髓中漿細胞的異常增生有關。診斷 AL 類澱粉沉積症通常需要結合血液和尿液檢查、影像學檢查、和組織活檢。而在治療方面,主要目的是減少異常蛋白質的產生,通常會採用化療藥物或幹細胞移植來控制病情發展,然而大多數的治療,對於晚期已經沉積在重要器官內的類澱粉是無效的。
「對於AL類澱粉樣變症而言,及早和準確的診斷,對於取得積極的治療效果是至關重要。」Boston Medical Center和波士頓大學醫學院澱粉樣變中心主任Dr. Vaishali Sanchorawala醫生指出,「降低輕鏈蛋白的產生,和清除重要器官中的類澱粉沉積,是希望改善整體生存率的重要門檻。」